2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5258 Host-virus genomic convergence on MYC defines the pathogenesis of KSHV-associated lymphomas

Saber Tadros, MD, Kathryn Lurain, MD, MPH2, Ramya Ramaswami, MBBS, MPH3, Kristena Yossef, MD4, Andrew Scott Warren, PhD5, Oscar W Biesanz6, Armando Filie7, Robert Yarchoan, MD8, Stefania Pittaluga Jr, MD9, Elaine Jaffe, MD10
1 University of Nebraska Medical Center, Omaha, Nebraska, United States
2 The Ohio State University Medical Center, Columbus, United States
3 National Institutes of Health, Bethesda, United States
4 University of Nebraska Medical Center, Omaha, United States
5 University of Virginia, Charlottesville, United States
6 University of Nebraska Medical Center, Omaha, United States
7 National Institutes of Health, Bethesda, United States
8 National Institutes of Health, Bethesda, United States
9 National Institutes of Health, Bethesda, United States
10 National Institutes of Health, Bethesda, United States

Background:

Kaposi sarcoma herpesvirus (KSHV/HHV8) is associated with aggressive B-cell lymphomas that  include primary effusion lymphoma (PEL), extracavitary PEL (EC-PEL) and HHV8-positive diffuse large B-cell lymphoma (HHV8+ DLBCL). Genomic characterization of these tumors is limited.  We hypothesized that integrated analysis of host and viral genomes would identify recurrent molecular mechanisms driving lymphomagenesis across participants with KSHV-associated lymphomas evaluated at a tertiary referral center.

Methods:

Whole-exome sequencing was performed on 57 KSHV-associated lymphoid malignancies (PEL, EC-PEL, and HHV8+ DLBCL) diagnosed between 2000 and 2022 identified from the archives of the Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI). Specimens consisted of formalin-fixed paraffin-embedded (FFPE) tissue from lymph node biopsies, extranodal tissue biopsies, and cell pellets prepared from serous effusions (pleural, peritoneal, or pericardial fluid), depending on disease presentation. The study was conducted under NIH IRB-approved protocols (10CN074,17C0174, NCT00006518, NCT03300830).

DNA was extracted from FFPE tissue sections or FFPE-derived cell pellets using Ionic G2 chemistry (Bionano Genomics). Whole-exome libraries were prepared using the Agilent SureSelect XT Human All Exon V5 + UTR enrichment kit and sequenced on the Illumina HiSeq 3000 platform. Targeted hybrid capture using a custom SureSelect design was additionally performed to enrich KSHV and EBV genomes for viral sequencing. Driver gene analysis was performed using dNdScv, MutSigCV, OncodriveFML, and HotMAPS. Candidate driver genes were required to achieve statistical significance after Benjamini-Hochberg correction for multiple testing (false discovery rate [FDR] <0.05).

The study cohort comprised predominantly male patients (53/57, 92%), reflecting the epidemiology of KSHV-associated lymphomas. HIV infection status was available for all patients; 55 of 57 (96%) were HIV-positive.

Results

PEL and EC-PEL demonstrated recurrent amplification of chromosome 8q24.21 encompassing MYC, accompanied by MYC protein overexpression. Recurrent mutations affected multiple MYC-regulatory genes, including TET2 (17%), TRRAP (17%), ACACB (18%), UTY (18%), and NCOR2 (11%), while chromatin remodeling genes (CREBBP, ARID1A, ARID2, and SMARCA4) were also recurrently altered, collectively supporting MYC dysregulation. Driver analysis identified TET2 as a significantly selected gene. Recurrent mutations in the Y chromosome genes UTY and KDM5D emerged as candidate driver events.

Mutational signature analysis demonstrated predominant APOBEC-associated mutagenesis together with age-related signatures, while recurrent alterations in DNA damage response genes (TP53BP1, CHD5, USP20, and NFRKB) suggested impaired checkpoint control in the setting of MYC activation. Viral genome sequencing identified enrichment of recurrent loss-of-function vIRF3 variants in PEL/EC-PEL, providing an independent viral mechanism predicted to enhance MYC activity. In contrast, genomic alterations were not significantly associated with EBV status or viral burden.

Conclusions:

Integrated host and viral genomic analysis demonstrate that MYC activation is a unifying molecular hallmark of KSHV-associated lymphomas. Convergent host alterations affecting MYC regulatory pathways together with viral variants predicted to enhance MYC activity define a common pathogenic mechanism underlying these tumors. These findings nominate MYC as a candidate therapeutic target and provide a rationale for functional evaluation of MYC-directed therapies in KSHV-associated lymphomas.

Saber Tadros, MD: No relevant conflicts of interest to declare.